Focus Investment Banking

JANUARY 18, 2024

In that environment, very few firms sought IPOs, and there was a major slowdown in overall exits, whether private or public. And will that mean that some of the privately held management consulting firms or other professional services companies will choose an IPO this year? Contact Kelly at Kelly.Kittrell@focusbankers.com.

IPO 52

IPO Consulting Corporate Finance Professional Services 52

Cooley M&A

OCTOBER 29, 2020

is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. A distinct feature of SPAC 3.0

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

MARCH 2, 2021

A SPAC is a publicly traded shell company with no underlying operating business that seeks to merge with a target operating company. According to Nasdaq , in 2015, SPACs made up approximately 12% of the IPO market, but by 2020, that number had risen to approximately 53%. What is a SPAC. In In re Benjamin H.

Securities 40

Securities IPO Shares Mergers and Acquisitions 40

Cooley M&A

JANUARY 22, 2021

Although global deal value was a subdued $966 billion in the first half of 2020 (down nearly 50% compared to the first half of 2019), momentum skyrocketed in the second half of the year to nearly $2.2 compared to 2019. compared to 2019, and up even higher (57%) when looking solely at US deal value. COVID-19: The New Normal.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Voting agreements in public M&A transactions.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 20, 2022

on transactions over 2019’s mega?mergers. A healthy 90 biopharma M&A transactions were announced in 2021 (compared to 69 in 2020 and 70 in 2019, the most transactions since 2016). But deal value – which totaled $108 billion as of December 15, 2021 – was slightly down from 2020 and significantly down from 2019.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40